{
    "root": "d9a4185e-43fa-4aeb-9b0f-8db01b166038",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Emtricitabine, Rilpivirine, Tenofovir Disoproxil Fumarate",
    "value": "20241214",
    "ingredients": [
        {
            "name": "EMTRICITABINE",
            "code": "G70B4ETF4S"
        },
        {
            "name": "RILPIVIRINE HYDROCHLORIDE",
            "code": "212WAX8KDD"
        },
        {
            "name": "TENOFOVIR DISOPROXIL FUMARATE",
            "code": "OTT9J7900I"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE 2910 (15000 MPA.S)",
            "code": "288VBX44JC"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 112",
            "code": "X7XJ6RM9Q2"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "emtricitabine , rilpivirine tenofovir disoproxil fumarate tablets indicated complete regimen treatment hiv-1 infection adults pediatric patients weighing least 35 kg : •as initial therapy antiretroviral treatment history hiv-1 rna less equal 100,000 copies/ml start therapy •to replace stable antiretroviral regimen virologically suppressed ( hiv-1 rna less 50 copies/ml ) stable antiretroviral regimen least 6 months treatment failure known substitutions associated resistance individual components emtricitabine , rilpivirine tenofovir disoproxil fumarate tablets [ microbiology ( 12.4 ) ( 14 ) ] . limitations : •more rilpivirine-treated subjects hiv-1 rna greater 100,000 copies/ml start therapy experienced virologic failure ( hiv-1 rna ≥ 50 copies/ml ) compared rilpivirine-treated subjects hiv-1 rna less equal 100,000 copies/ml [ ( 14 ) ] .",
    "contraindications": "• testing : prior initiating emtricitabine , rilpivirine tenofovir disoproxil fumarate tablets , test hepatitis b virus infection . prior initiation treatment emtricitabine , rilpivirine tenofovir disoproxil fumarate tablets , clinically appropriate schedule , assess serum creatinine , estimated creatinine clearance , urine glucose , urine protein patients . patients chronic kidney disease , also assess serum phosphorus . ( 2.1 ) • recommended adults pediatric patients weighing least 35 kg : one tablet taken orally daily food . ( 2.2 ) • pregnant patients already emtricitabine , rilpivirine tenofovir disoproxil fumarate tablets prior pregnancy virologically suppressed ( hiv-1 rna less 50 copies per ml ) , one tablet taken daily may continued . lower exposures rilpivirine observed pregnancy ; therefore , viral load monitored closely . ( 2.3 ) • renal impairment : recommended patients estimated creatinine clearance 50 ml per minute . ( 2.4 ) • recommended rifabutin coadministration : additional 25 mg tablet rilpivirine ( edurant ® ) per day taken concomitantly emtricitabine , rilpivirine tenofovir disoproxil fumarate tablets meal duration rifabutin coadministration . ( 2.5 , 7.6 , 12.3 )",
    "warningsAndPrecautions": "emtricitabine , rilpivirine tenofovir disoproxil fumarate tablets available containing 200 mg emtricitabine , 27.5 mg rilpivirine hydrochloride equivalent 25 mg rilpivirine , 300 mg tenofovir disoproxil fumarate equivalent 245 mg tenofovir disoproxil . 200 mg/25 mg/300 mg tablets yellow , film-coated , capsule shaped , unscored tablets debossed one side tablet ert side . available follows : ndc 0378-5440-93bottles 30 tablets ndc 0378-5440-77bottles 90 tablets store 20° 25°c ( 68° 77°f ) . [ usp controlled room temperature . ] keep container tightly closed . dispense original container .",
    "adverseReactions": "emtricitabine , rilpivirine tenofovir disoproxil fumarate tablets contraindicated coadministered following drugs ; coadministration may result loss virologic response possible resistance emtricitabine , rilpivirine tenofovir disoproxil fumarate tablets class nnrtis [ ( 5.7 ) , ( 7 ) , pharmacology ( 12.3 ) ] : •anticonvulsants : carbamazepine , oxcarbazepine , phenobarbital , phenytoin •antimycobacterials : rifampin , rifapentine •glucocorticoid ( systemic ) : dexamethasone ( single-dose ) •herbal products : st john ’ wort ( hypericum perforatum ) •proton pump inhibitors : e.g . , dexlansoprazole , esomeprazole , lansoprazole , omeprazole , pantoprazole , rabeprazole",
    "indications_original": "Emtricitabine, rilpivirine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg:\n                  \n                     \n                        •as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy or\n                     \n                        •to replace a stable antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no treatment failure and no known substitutions associated with resistance to the individual components of emtricitabine, rilpivirine and tenofovir disoproxil fumarate tablets [see Microbiology (12.4) and Clinical Studies (14)].\n                  \n                  Limitations of Use:\n                  \n                     \n                        •More rilpivirine-treated subjects with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure (HIV-1 RNA ≥ 50 copies/mL) compared to rilpivirine-treated subjects with HIV-1 RNA less than or equal to 100,000 copies/mL [see Clinical Studies (14)].",
    "contraindications_original": "• Testing: Prior to or when initiating emtricitabine, rilpivirine and tenofovir disoproxil fumarate tablets, test for hepatitis B virus infection. Prior to initiation and during treatment with emtricitabine, rilpivirine and tenofovir disoproxil fumarate tablets, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. ( 2.1 ) • Recommended dosage in adults and pediatric patients weighing at least 35 kg: One tablet taken orally once daily with food. ( 2.2 ) • For pregnant patients who are already on emtricitabine, rilpivirine and tenofovir disoproxil fumarate tablets prior to pregnancy and who are virologically suppressed (HIV-1 RNA less than 50 copies per mL), one tablet taken once daily may be continued. Lower exposures of rilpivirine were observed during pregnancy; therefore, viral load should be monitored closely. ( 2.3 ) • Renal impairment: Not recommended in patients with estimated creatinine clearance below 50 mL per minute. ( 2.4 ) • Recommended dosage with rifabutin coadministration: an additional 25 mg tablet of rilpivirine (Edurant ® ) once per day taken concomitantly with emtricitabine, rilpivirine and tenofovir disoproxil fumarate tablets and with a meal for the duration of the rifabutin coadministration. ( 2.5 , 7.6 , 12.3 )",
    "warningsAndPrecautions_original": "Emtricitabine, Rilpivirine and Tenofovir Disoproxil Fumarate Tablets are available containing 200 mg of emtricitabine, 27.5 mg of rilpivirine hydrochloride equivalent to 25 mg of rilpivirine, and 300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil.\n                  The 200 mg/25 mg/300 mg tablets are yellow, film-coated, capsule shaped, unscored tablets debossed with M on one side of the tablet and ERT on the other side. They are available as follows:\n                  NDC 0378-5440-93bottles of 30 tablets\n                  NDC 0378-5440-77bottles of 90 tablets\n                  \n                     Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]\n                  \n                  Keep container tightly closed.\n                  Dispense only in original container.",
    "adverseReactions_original": "Emtricitabine, rilpivirine and tenofovir disoproxil fumarate tablets are contraindicated when coadministered with the following drugs; coadministration may result in loss of virologic response and possible resistance to emtricitabine, rilpivirine and tenofovir disoproxil fumarate tablets or to the class of NNRTIs [see Warnings and Precautions (5.7), Drug Interactions (7), and Clinical Pharmacology (12.3)]:\n                  \n                     \n                        •Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin\n                     \n                        •Antimycobacterials: rifampin, rifapentine\n                     \n                        •Glucocorticoid (systemic): dexamethasone (more than a single-dose)\n                     \n                        •Herbal Products: St John’s wort (Hypericum perforatum)\n                     \n                        •Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole"
}